



November 28, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Foundation Earns CRISIL's Highest VO 1A Rating for Excellence in Social Responsibility."

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com

Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Foundation Earns CRISIL's Highest VO 1A Rating for Excellence in Social Responsibility

Mumbai, Pune, November 28, 2025: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of global pharma major Lupin Limited (Lupin), has been awarded the CRISIL Voluntary Organisation grading of VO 1A, the highest classification, indicating 'Very Strong Delivery Capability and High Financial Proficiency.'

This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility. For over 37 years, LHWRF has spearheaded initiatives to improve lives and livelihoods and strengthen healthcare for underserved populations across India. The Foundation remains dedicated to empowering communities and promoting holistic development.

"We are honored to receive the VO 1A rating from CRISIL, reflecting our commitment to social welfare and sustainable growth," said **Tushara Shankar, Head – CSR, Lupin**. "This recognition inspires us to expand our innovative programs that support communities and create lasting positive impact."

The CRISIL VO grading is a comprehensive assessment framework that evaluates an organization's overall ability to deliver on its goals. It focuses on factors such as stakeholder engagement, system and process efficiency, implementation and monitoring mechanisms, and financial management skills, including revenue and expenditure control, resource diversification, liquidity, and transparency reporting.

About LHWRF

Lupin Human Welfare & Research Foundation (LHWRF) is the social responsibility arm of Lupin Limited, founded by Dr. Desh Bandhu Gupta in 1988. Over the past three decades, the Foundation has impacted more than 2.02 million beneficiaries across 5,400 villages in 26 districts spread across eight states in India.

Throughout its journey, the Foundation has primarily focused on creating sustainable livelihood opportunities and fostering economic growth in some of the most underdeveloped districts in the country. It adopts a family-centered approach and implements measures to help break the cycle of poverty, thereby positively impacting the lives and livelihoods of its beneficiaries.

The Livelihoods Program, a key driver of our development efforts over the last decade, delivers sustainable solutions for vulnerable communities through capacity building, natural resource management, livestock development, strengthened value chains, and improved market access for farmers. The Lives Program

Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

enhances community well-being and healthcare access by strengthening health systems to effectively address non-communicable diseases such as COPD, CVD, asthma, diabetes, and hypertension.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries, please contact:

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

rajalakshmi.azariah@lupin.com